Jacob R. Haling

Genomics Institute of the Novartis Research Foundation

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor”.

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Nature Medicine(2022)10.1038/s41591-022-02007-7

N/A

0DataRank · unranked

519 citations

Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom +25 more

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c00741

N/A

0DataRank · unranked

95 citations

Jacob R. Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns +21 more

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant Tumors

Research Square(2022)10.21203/rs.3.rs-1261963/v1

N/A

0DataRank · unranked

1 citations

Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis +25 more

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0870

N/A

0DataRank · unranked

33 citations

Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan +29 more